Akebia Therapeutics Announces Multiple Positive Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
January 14, 2025 11:06 AM ESTH.C. Wainwright analyst Ed Arce reiterated a Buy rating and $7.50 price target on Akebia Therapeutics (NASDAQ: AKBA)
The analyst comments "Affirm Buy and $7.50 PT. We employ a rNPV model to value AKBA shares. Our price target currently consists of: (1) $4.17... More
